cor2ed
engage checkpoint medical linkedin twitter
bg

Targeting NTRK gene fusions

Targeting NTRK gene fusions

Prof. Fernando López-Ríos, Prof. Andrea Sartore-Bianchi, Assoc. Prof. Gerald Prager, Dr Jaclyn Hechtman

Targeting NTRK gene fusions on the ESMO OncologyPRO portal as a key resource relating to the detection and management of TRK fusion-positive cancer.
Portrait of Fernando López-Ríos
Prof. Fernando López-Ríos

Pathologist

Hospital Universitario HM Sanchnarro Universidad CEU San Pablo

Spain

Portrait of Andrea Sartore-Bianchi
Prof. Andrea Sartore-Bianchi

Medical Oncologist

Niguarda Cancer Center

Italy

Portrait of Gerald Prager
Assoc. Prof. Gerald Prager

Medical Oncologist

Medical University of Vienna

Austria

Portrait of Dr Jaclyn Hechtman
Dr Jaclyn Hechtman

Pathologist

Memorial Sloan Kettering Cancer Center

United States (US)

preview next

time OncologyPRO | open 30 min | Sep 2019

temporal

I agree that this educational programme:

Targeting NTRK gene fusions

Prof. Andrea Sartore-Bianchi (medical oncologist), Assoc. Prof. Gerald Prager (medical oncologist), Dr Jaclyn Hechtman (molecular and surgical pathologist) and Prof. Fernando Lopez-Ríos (molecular and surgical pathologist) developed this educational resource.  With over 50,000 visits in 2 years, healthcare professionals continue to value the diagnostic and treatment guidance provided.

This resource aims to:

  1. Explore the importance of TRK fusion proteins as a therapeutic target and understand the clinical use of TRK inhibitors.
  2. Explain the mechanisms behind TRK fusion-driven tumour biology.
  3. Provide an overview of the different techniques used for NTRK gene fusion testing.
  4. Provide recommendations on testing for TRK fusion proteins

These topics are addressed over two modules. Module 1 provides an overview of cancers with NTRK gene fusions and their testing. Available treatments and those under development that target these fusions are also discussed. Module 2 provides an overview of how testing for NTRK gene fusions allows for the identification of patients who may benefit from TRK inhibitor therapy. The range of NTRK gene fusion testing methodologies available are reviewed.

COR2ED have donated this content to ESMO to ensure that the practical guide reflects today's best clinical practice in detecting and treating TRK fusion-positive cancer.

NTRK CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer.

Other programmes of interest

Other programmes developed by Prof. Fernando López-Ríos

Other programmes developed by Prof. Andrea Sartore-Bianchi

Portrait of Andrea Sartore-Bianchi
Prof. Andrea Sartore-Bianchi

Medical Oncologist

Niguarda Cancer Center

Italy

preview next

Other programmes developed by Assoc. Prof. Gerald Prager

Portrait of Gerald Prager
Assoc. Prof. Gerald Prager

Medical Oncologist

Medical University of Vienna

Austria

preview next